eISSN 1738-8872
pISSN 1017-7825
pISSN 1017-7825
Table. 4.
Table. 4.
Antibiotic resistance profile of
| Antibiotic class | Antibiotic | Clear zone diameter (mm) | R/S/I |
|---|---|---|---|
| Aminopenicillin | Ampicillin (10 µg) |
49 ± 0.60 | S |
| Bacitracin | Bacitracin (10 IU) |
58 ± 2.31 | S |
| Glycopeptide | Vancomycin (30 µg) |
48 ± 2.65 | S |
| Cephalosporine | Cefoxitin (30 µg) |
26 ± 3.21 | S |
| β-Lactams | Oxacillin (1 µg) |
6 ± 0.00 | R |
| Amphenicols | Chloramphenicol (30 µg) |
63 ± 2.08 | S |
| Macrolides | Erythromycin (15 µg) |
62 ± 1.53 | S |
| Streptomycin (10 µg) |
37 ± 2.52 | S | |
| Aminoglycosides | Kanamycin (30 µg) |
20 ± 4.00 | S |
| Tetracycline | Tetracycline (30 µg) |
57 ± 2.65 | S |
| Clindamycin (2 µg) |
56 ± 5.51 | S | |
| Lincosamides | Lincomycin (2 µg) |
50 ± 3.61 | S |
| Pleuromutilins | Lefamulin (20 µg) |
75 ± 2.08 | S |
| Monocarboxylic acid | Mupirocin (200 µg) |
11 ± 1.15 | R |
| Quinolones | Ciprofloxacin (5 µg) |
32 ± 2.89 | S |
| Rifampicin | Rifampicin (5 µg) |
64 ± 1.15 | S |
| Sulfonamide | Sulfonamide (300 µg) |
7 ± 1.15 | R |
Diameter of clear zone/inhibition zone was presented as the mean of three experiments ± SD. aInhibition zone was based on [58]. bInhibition zones of oxacillin and clindamycin were based on CLSI standard described by [59]. cInhibition zone of lincomycin was based on [60]. dInhibition zone of mupirocin was based on [61]. eInhibition zone of lefamulin was based on interpretative criteria results of
J. Microbiol. Biotechnol. 2024;34:871~879 https://doi.org/10.4014/jmb.2311.11031
© J. Microbiol. Biotechnol.